Work

Figure 2 from Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial

Year: 2026

Type: other

Abstract: Clinical response to benralizumaba in the total cohort and by culprit agent. Change in BSA and HRQoL from baseline to week 4. aResponse was defined as a reduction in ercAE to grade ≤ 1 by week 4. PI3Ki, PI3K inhibitor. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

DOI: 10.1158/1078-0432.33143631

Authors: Mario E. Lacouture, Alexander Pan, Tara Maier, Anna Chen, George Dranitsaris, Neil J. Shah, Chau Dang, Devika Gajria, Allison Gordon, Neil Iyengar, Pedram Razavi, Mark Robson, Ezra Rosen, Serena Wong, Ucalene Harris, Kwami Ketosugbo, Cindy Bravo, Manu Jain, Alina Markova

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7172282935

Cites:

Cited by:

Related to: